Formulation and evalution of Transdermal patches of torasemide

Rajesh Asija, Avinash Gupta, Bhagwan Swaroop Maheshwari


The main advantage of Transdermal drug delivery system is to bypass the first pass metabolism, avertance of the risk and annoyance of intravenous therapy and of the varied conditions of absorption, like pH changes, gastric emptying time and presence of enzyme. The Transdermal drug delivery scheme is generally used where the others system of drug administration fails or it is mainly used in edema associates congestive heart failure. The transdermal drug delivery has advantage to deliver medicines via skin to systemic circulation at a predetermined rate and maintain therapeutic concentration for prolong period of time. This review describes the assorted formulation aspects, a variety of excipients, evaluation tests, challenges and drugs explored in the pasture of topical drug delivery.


Transdermal patches, Skin, Controlled Drug Delivery System

Full Text:



Kathryn E U, Scott M C, Robert S L, et al. Polymeric systems for controlled drug release. Chemical Review. 1999; 99: 3181-3198.

Chain Y W, et al. Sustained and controlled release drug delivery systems. International Journal and Review.1978; 223-227.

Saroha K, Yadav B, Sharma B. Transdermal patch: a discrete dosage form, International Journal of Current Pharmaceutical Research. 2011; 3(3): 98-108.

Morrow D I J, McCarron P A. et al. Innovative strategies for enhancing topical and transdermal drug delivery, The Open Drug Delivery Journal.2007; 1:36-59.

Finnin B C, Morgan T M, Trasndermal penetration. Journal of Pharmaceutical Science. 1999; 88(10):955-958.

Barry B. Transdermal drug delivery. The Science of Dosage Form Design.2002; 499-533.

Cleary G W. Transdermal controlled release systems. Medical Applications of Controlled Release. 2001; 203-251.

Vyas S P, Khar R K, Controlled drug delivery: concepts and advances, Vallabh Prakashan.2002; 411-447.

Allen L V, Popovich N G, Ansel H C. Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems, 8th Edition, Lippincott Williams & wilkins, 2005; 298- 315.

Matt V, Waterman J, Ian McNab, et al. Basic physiology of the skin, Basic Science, Surgery.2010; 469-472.

Keleb E, Sharma R K, Mosa E B, et al. Transdermal drug delivery system- design and evaluation, International Journal of Advances in Pharmaceutical Sciences, 2010;1: 201-211.

Sheth N S, Mistry R B, et al. Formulation and evaluation of transdermal patches and to study permeation enhancement effect of Eugenol. Journal of Applied Pharmaceutical Science, 2011; 1 (3): 96-101.

Active Transdermal Delivery, Greystone Associates, 2007; 125. Available at

Kandavilli S, Nair Vinod and Panchagnula Ramesh, Polymers in transdermal drug delivery systems, Pharmaceutical Technology 2002; 26(5): 62-80.

Singh Somnath. An overview of transdermal drug delivery. Industry Overview and Deals. Drug Delivery Report Autumn/Winter 2005:35-40. Available at:

Prausnitz Mark. R., Mitragotri Samir., Langer Robert. Current status and future potential of transdermal drug delivery. Nature Review. Drug Discovery, 2004; 3: 115-124.

Benson H A E. Transdermal drug delivery: penetration enhancement techniques. Current Drug Delivery 2005; 2:23-33.

Agarwal S S, Pruthi J. Development and evalution of matrix type transdermal patch of ethinylestradiol & medroxyprogesterone acetate for anti implantation activity in femal wistar rats, Contraception, 2011; 84(5): 533 – 538.

Yanli Gao, Jinying Liang, Jianping Liu, Yan Xiao. Double layer weekly sustained release transdermal patch containing gestodene and ethinylestradiol. International Journal of Pharmaceutics. 2009; 377, 128-134.

Ji Hui Zhao, Ji-Hua Fu, Shu-Ming Wang, A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: In vitro and in vivo characterization, Int. J. of pharmaceutics, 2007; 337(1-2): 88-101.

Vormfelde SV, et al. Torsemide renal clearance and genetic variation in luminal and basolateral organic anion transporters. British Journal of Clinical Pharmacology. 2006; 323-335.

Posina Anitha, Sundarapandiyan R. et al., preparation in vitro and in vivo characterization of transdermal patch containing glibenclamide and atenolol: A combination approach, Pakistan Journal Pharmaceutical Sciences.2011; 24 (2): 155 – 163.

Fortuno A, et al. The loop diuretic torsemide interfere with endothelin-1 actions in the aorta of hypertensive rats. Nephrology Dialysis Transplantation 2009; 342-348.

Karagueuzian H S, et al. Targeting cardiac fibrosis: a new frontier in antiarrhythmic therapy. American Journal of Cardiovascular Disease. 2011; 101-109.

Sankar V, Sivanand V, Ravichandran V. Design and evaluation of nifedipine transdermal patches. Indian Journal of Pharmaceutical Sciences. 2003; 65(5):510-5.


Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


  • There are currently no refbacks.

Copyright (c) 2015 International Journal of Advances in Scientific Research

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.